Compare TRVG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | TSHA |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.4M | 1.7B |
| IPO Year | 2015 | 2020 |
| Metric | TRVG | TSHA |
|---|---|---|
| Price | $5.63 | $5.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $3.95 | ★ $11.63 |
| AVG Volume (30 Days) | 119.5K | ★ 4.1M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $8.42 | $1,152.42 |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $2.59 | $2.53 |
| 52 Week High | $5.78 | $7.30 |
| Indicator | TRVG | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 64.85 | 43.52 |
| Support Level | $2.78 | $5.28 |
| Resistance Level | $5.70 | $6.01 |
| Average True Range (ATR) | 0.34 | 0.45 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 63.38 | 24.09 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.